Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodyna
The safety and tolerability of single and multiple administration of DWP212525
| Condition(s) | Autoimmune Diseases |
|---|---|
| Status | Recruiting |
| Phase | Phase 1 |
| Study type | Interventional |
| Summary | The safety and tolerability of single and multiple administration of DWP212525 |
| Who can participate | Inclusion Criteria: 1. Healthy adult volunteers aged 19 to 55 years 2. Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 30.0 kg/m2 3. Received a sufficient explanation on this study 4. Eligible as subjects in the study Exclusion Criteria: 1. History of diseases such as clinically significant disease of hepatobiliary 2. Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview 3. Hemato-oncologic diseases, including malignant tumor diagnosis 4. Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test |
| Ages | 19 Years to 55 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Daewoong Pharmaceutical Co. LTD. |
| Locations | Seoul, South Korea |
| Start date | 2024-12-10 |
| NCT ID | NCT06736587 |
| Official listing | https://clinicaltrials.gov/study/NCT06736587 |